Skip to main content

Menu

British National Formulary May 2025 Update

This update contains 6 significant changes, 4 dose changes, 3 new monographs and 1 deleted preparation.

Significant Changes:

  • Amphotericin B: review of indications and dose for liposomal preparations, as well as updates to directions for administration, breast-feeding, pregnancy, cautions, and monitoring advice.
  • Asthma, chronic: updated guidance on management.
  • Budesonide with formoterol (DuoResp Spiromax® 160 micrograms/4.5 micrograms): new indication and dose for mild asthma, reliever therapy.
  • Budesonide with formoterol (Fobumix® 160/4.5 Easyhaler): new indication and dose for mild asthma, reliever therapy.
  • Prolonged-release opioids: removal of indication for relief of post-operative pain [MHRA/CHM advice] (advice in all opioids; see example in oxycodone hydrochloride).
  • Smoking cessation: updated drug treatment guidance.

Dose Changes:

  • Fobumix® 80/4.5 Easyhaler (budesonide with formoterol) [update to dosing for asthma, maintenance therapy].
  • Fobumix® 160/4.5 Easyhaler (budesonide with formoterol) [update to dosing for asthma, maintenance therapy].
  • Fobumix® 320/9 Easyhaler (budesonide with formoterol) [update to dosing for asthma, maintenance therapy].
  • Rosuvastatin [update to dose adjustments due to interactions].

New Monographs:

  • Anzupgo® [delgocitinib].
  • Imdylltra® [tarlatamab].
  • Winlevi® [clascoterone].

Deleted Preparations:

  • Ambisome® [amphotericin B].